

DATE:	17 March 2025
TO:	All Zones: Physicians, Nurses and Healthcare Providers, Laboratory Staff
FROM:	Clinical Biochemistry
RE:	Changes to Insulin Testing

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- **Effective April 1, 2025**, the method used to measure insulin at Edmonton Base Lab (EBL) will change from Abbott Architect to Siemens Atellica, resulting in a wider reportable range.
- Similar to the Abbott Architect insulin assay, the Siemens Atellica insulin assay also detects common insulin analogs.

Background

- Nearly all insulin orders in the province are routed to EBL. The only exceptions are those collected at the University of Alberta Hospital and Kaye Edmonton Clinic.
- The Abbott Architect instrument will no longer be in-use at EBL, requiring the tests currently run on this instrument to be run on a different instrument.
- The Abbott Architect (current EBL assay) and Siemens Atellica (new EBL assay) detect common insulin analogs, while the Roche Cobas insulin assay at the University of Alberta Hospital (UAH) laboratory does not.

How this will impact you

- The range of insulin results reported at EBL will increase from 6-1596 pmol/L to 3-9000 pmol/L.
- Comments will now append to all insulin results indicating if the method detects common insulin analogs or not.

Action Required

- Be aware of the wider reportable range for insulin and new comments regarding insulin analog detection.
- There is no need to update order sets or preference lists as test codes will not change.

Questions/Concerns

- Edmonton Base Lab Clinical Chemist Team, 825-394-1816, apl.clinicalchemists@albertaprecisionlabs.ca

Approved by

- Dr. Mathew Estey, Medical Lead Clinical Biochemistry, Edmonton Base Lab
- Dr. Erene Farag, Associate Medical Director, Edmonton Base Lab